News

ascopubs.org6d
Immunotherapeutic response score to predict prognosis for unresectable hepatocellular carcinoma with immune checkpoint inhibitors-based conversion treatment.
Effect of cDC2 licensing by CCL5+ Th1 cells following BCL9/BCL9L inhibition on CD8+ T cell cross-priming for enhanced anti-tumor responses. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
ascopubs.org6d
Comparison of efficacy and safety of lenvatinib vs. apatinib in combination with hepatic arterial infusion chemotherapy and immune checkpoint inhibitors for unresectable ...
Effect of cDC2 licensing by CCL5+ Th1 cells following BCL9/BCL9L inhibition on CD8+ T cell cross-priming for enhanced anti-tumor responses. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...